ofloxacin has been researched along with Tuberculosis, Drug-Resistant in 145 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Ofloxacin and moxifloxacin are the most commonly used fluoroquinolones (FQs) for the treatment of tuberculosis." | 3.85 | Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. ( Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C, 2017) |
| " Further studies should determine the optimal pharmacodynamic target for moxifloxacin in a multidrug regimen and clarify safety issues when it is administered at higher doses." | 2.79 | Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. ( Charalambous, S; Chigutsa, E; Denti, P; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Mungofa, S; Simonsson, US; Sirgel, FA; Wiesner, L; Zvada, SP, 2014) |
| "Despite the important role of fluoroquinolones and the predominant use of ofloxacin for treating multidrug-resistant tuberculosis in South Africa, there are limited data on ofloxacin pharmacokinetics in patients with multidrug-resistant tuberculosis, no ofloxacin pharmacokinetic data from South African patients, and no direct assessment of the relationship between ofloxacin pharmacokinetics and the MIC of ofloxacin of patient isolates." | 2.77 | Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. ( Chigutsa, E; Harding, J; Kirkpatrick, CM; Mac Kenzie, WR; McIlleron, H; Meredith, S; Moodley, P; Padayatchi, N; Weiner, M; Wiesner, L, 2012) |
| "After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter." | 2.71 | [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. ( Li, SM; Xing, BC; Zheng, XM, 2004) |
| " We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin." | 1.51 | Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ( Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2019) |
| " Adverse events associated with second-line drugs (SLDs) can have severe impact on efficient management." | 1.43 | Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. ( Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016) |
| "Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children." | 1.42 | Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. ( Castel, S; Dooley, KE; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Seddon, JA; Thee, S; Wiesner, L, 2015) |
| " Drug exposures were lower than those in adults following standard doses and below the proposed pharmacodynamic targets, likely due to more rapid elimination in children." | 1.40 | Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. ( Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Norman, J; Schaaf, HS; Thee, S; van der Merwe, PL; Wiesner, L, 2014) |
| "Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility." | 1.37 | Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. ( Gey van Pittius, NC; Grobbelaar, M; Hernandez-Pando, R; Jimenez, A; Leon, R; Louw, GE; McEvoy, CR; Murray, M; van Helden, PD; Victor, TC; Warren, RM, 2011) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| " Mean +/- SD of Cmax was 9." | 1.32 | Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ( Chierakul, N; Chindavijak, B; Chulavatnatol, S; Klomsawat, D, 2003) |
| "Levofloxacin was found to be more efficacious than ofloxacin when incorporated into multidrug regimens used for treatment of MDR-TB." | 1.32 | Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. ( Chan, CK; Chau, CH; Lee, J; Leung, CC; Tam, CM; Wong, PC; Yew, WW, 2003) |
| "Ofloxacin has been advocated by the WHO in case of MDR-TB, when susceptibility to test results are not available before starting the new treatment, in the continuation period (18 months) and if resistance is proven to at least isoniazid and rifampicin." | 1.32 | Ofloxacin in multidrug resistant tuberculosis. ( Gawde, AS; Morye, VK; Walwaikar, PP, 2003) |
| "We report a chronic case of pulmonary tuberculosis in a Malagasy citizen from Antsohihy (West of Madagascar), who was infected with a multi-drug resistant Mycobacterium bovis strain." | 1.32 | [A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar]. ( Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V, 2003) |
| " This case series describes the probable association between multiple adverse events and the use of pyrazinamide and levofloxacin in the treatment of individuals with suspected latent multidrug-resistant tuberculosis infection." | 1.31 | Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. ( Dolovich, LR; Holbrook, A; Loeb, M; Papastavros, T; Whitehead, L, 2002) |
| "Treatment with ofloxacin in a combined regimen achieved a success rate of 78%." | 1.30 | Quinolones and multidrug-resistant tuberculosis. ( Maranetra, KN, 1999) |
| "Ciprofloxacin was used primarily to treat Mycobacterium avium complex (MAC) infection, dosed to achieve 2-hour post-dose serum concentrations of 4-6 micrograms/ml." | 1.29 | Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. ( Berning, SE; Iseman, MD; Madsen, L; Peloquin, CA, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (15.17) | 18.2507 |
| 2000's | 38 (26.21) | 29.6817 |
| 2010's | 73 (50.34) | 24.3611 |
| 2020's | 12 (8.28) | 2.80 |
| Authors | Studies |
|---|---|
| Sureram, S | 1 |
| Senadeera, SP | 1 |
| Hongmanee, P | 1 |
| Mahidol, C | 1 |
| Ruchirawat, S | 1 |
| Kittakoop, P | 1 |
| Rahman, SMM | 1 |
| Nasrin, R | 1 |
| Rahman, A | 1 |
| Ahmed, S | 2 |
| Khatun, R | 1 |
| Uddin, MKM | 1 |
| Rahman, MM | 1 |
| Banu, S | 2 |
| Wu, X | 1 |
| Tan, G | 1 |
| Sha, W | 1 |
| Liu, H | 1 |
| Yang, J | 1 |
| Guo, Y | 1 |
| Shen, X | 1 |
| Wu, Z | 1 |
| Shen, H | 1 |
| Yu, F | 2 |
| Jia, QJ | 1 |
| Zeng, MC | 1 |
| Xie, L | 1 |
| Cheng, QL | 1 |
| Huang, YY | 1 |
| Li, QC | 1 |
| Wu, YF | 1 |
| Ai, LY | 1 |
| Lu, M | 1 |
| Fang, ZJ | 1 |
| Sy, KTL | 1 |
| Leavitt, SV | 1 |
| de Vos, M | 1 |
| Dolby, T | 1 |
| Bor, J | 1 |
| Horsburgh, CR | 1 |
| Warren, RM | 4 |
| Streicher, EM | 2 |
| Jenkins, HE | 1 |
| Jacobson, KR | 2 |
| Pietersen, E | 1 |
| Anderson, K | 1 |
| Cox, H | 2 |
| Dheda, K | 2 |
| Bian, A | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 2 |
| van der Heijden, YF | 1 |
| Hu, Y | 3 |
| Chi, Y | 1 |
| Feng, X | 1 |
| Li, H | 1 |
| Shang, Y | 1 |
| Pan, J | 1 |
| Pang, Y | 3 |
| Herricks, T | 1 |
| Donczew, M | 1 |
| Mast, FD | 1 |
| Rustad, T | 1 |
| Morrison, R | 1 |
| Sherman, DR | 1 |
| Aitchison, JD | 1 |
| Gupta, A | 2 |
| Sinha, P | 2 |
| Rathod, S | 2 |
| Shanmugam, SK | 1 |
| Uma Devi, KR | 1 |
| Anupurba, S | 2 |
| Nema, V | 2 |
| Sayadi, M | 1 |
| Zare, H | 1 |
| Jamedar, SA | 1 |
| Hashemy, SI | 1 |
| Meshkat, Z | 1 |
| Soleimanpour, S | 1 |
| Hoffner, S | 3 |
| Ghazvini, K | 1 |
| Safari, M | 1 |
| Moghim, S | 1 |
| Salehi, M | 1 |
| Jafari, R | 1 |
| Nasr Esfahani, B | 1 |
| Davies Forsman, L | 1 |
| Niward, K | 1 |
| Kuhlin, J | 1 |
| Zheng, X | 2 |
| Zheng, R | 2 |
| Ke, R | 1 |
| Hong, C | 1 |
| Werngren, J | 2 |
| Paues, J | 1 |
| Simonsson, USH | 1 |
| Eliasson, E | 1 |
| Xu, B | 2 |
| Alffenaar, JW | 1 |
| Schön, T | 1 |
| Bruchfeld, J | 1 |
| Liu, Q | 1 |
| Yang, D | 1 |
| Qiu, B | 1 |
| Martinez, L | 1 |
| Ji, Y | 1 |
| Song, H | 1 |
| Li, Z | 1 |
| Wang, J | 1 |
| Wang, Z | 1 |
| Xie, T | 1 |
| Mu, C | 1 |
| Wang, C | 2 |
| Ju, H | 1 |
| Zhao, H | 1 |
| Sun, R | 1 |
| Luo, T | 1 |
| Yuan, J | 1 |
| Peng, X | 1 |
| Yang, G | 1 |
| Mi, Y | 1 |
| Sun, C | 1 |
| Zhang, C | 1 |
| Bao, L | 1 |
| Bablishvili, N | 2 |
| Tukvadze, N | 2 |
| Shashkina, E | 1 |
| Mathema, B | 1 |
| Gandhi, NR | 1 |
| Blumberg, HM | 2 |
| Kempker, RR | 3 |
| Guglielmetti, L | 1 |
| Varaine, F | 1 |
| Huerga, H | 1 |
| Bonnet, M | 1 |
| Rich, ML | 1 |
| Mitnick, CD | 3 |
| Arora, J | 1 |
| Kumar, G | 1 |
| Verma, AK | 1 |
| Bhalla, M | 1 |
| Singhal, R | 1 |
| Sarin, R | 1 |
| Myneedu, VP | 1 |
| Alene, KA | 1 |
| Yi, H | 1 |
| Viney, K | 1 |
| McBryde, ES | 2 |
| Yang, K | 1 |
| Bai, L | 1 |
| Gray, DJ | 1 |
| Clements, ACA | 1 |
| Xu, Z | 1 |
| Pal, SK | 1 |
| Pandey, D | 1 |
| Fakir, NA | 1 |
| Sinha, D | 1 |
| SivaKumar, S | 1 |
| Periera, M | 1 |
| Balgam, S | 1 |
| Sekar, G | 2 |
| UmaDevi, KR | 1 |
| Mamatha, HG | 1 |
| Shanthi, V | 1 |
| Atif, M | 2 |
| Bashir, A | 1 |
| Ahmad, N | 6 |
| Fatima, RK | 1 |
| Saba, S | 1 |
| Scahill, S | 1 |
| Liang, YP | 1 |
| Chen, Y | 2 |
| Xiao, TY | 1 |
| Xia, Q | 2 |
| Liu, HC | 2 |
| Zhao, XQ | 2 |
| Zeng, CY | 1 |
| Zhao, LL | 2 |
| Wan, KL | 2 |
| Yang, Y | 2 |
| Niehaus, KE | 1 |
| Walker, TM | 1 |
| Iqbal, Z | 1 |
| Walker, AS | 1 |
| Wilson, DJ | 1 |
| Peto, TEA | 1 |
| Crook, DW | 1 |
| Smith, EG | 1 |
| Zhu, T | 1 |
| Clifton, DA | 1 |
| Oudghiri, A | 1 |
| Karimi, H | 1 |
| Chetioui, F | 1 |
| Zakham, F | 1 |
| Bourkadi, JE | 1 |
| Elmessaoudi, MD | 1 |
| Laglaoui, A | 1 |
| Chaoui, I | 1 |
| El Mzibri, M | 1 |
| de Oliveira, LP | 1 |
| Carneiro, ZA | 1 |
| Ribeiro, CM | 1 |
| Lima, MF | 1 |
| Paixão, DA | 1 |
| Pivatto, M | 1 |
| de Souza, MVN | 1 |
| Teixeira, LR | 1 |
| Lopes, CD | 1 |
| de Albuquerque, S | 1 |
| Pavan, FR | 1 |
| Guerra, W | 1 |
| Javaid, A | 5 |
| Afridi, AK | 3 |
| Basit, A | 3 |
| Khan, AH | 4 |
| Ahmad, I | 3 |
| Doan, TN | 1 |
| Cao, P | 1 |
| Emeto, TI | 1 |
| McCaw, JM | 1 |
| Al-Shaer, MH | 1 |
| Alghamdi, WA | 1 |
| Alsultan, A | 1 |
| An, G | 1 |
| Alkabab, Y | 1 |
| Barbakadze, K | 1 |
| Houpt, E | 1 |
| Kipiani, M | 1 |
| Mikiashvili, L | 1 |
| Cegielski, JP | 1 |
| Heysell, SK | 2 |
| Peloquin, CA | 7 |
| Ahmed, I | 1 |
| Jabeen, K | 1 |
| Inayat, R | 1 |
| Hasan, R | 2 |
| Jnawali, HN | 1 |
| Hwang, SC | 1 |
| Park, YK | 2 |
| Kim, H | 2 |
| Lee, YS | 1 |
| Chung, GT | 1 |
| Choe, KH | 1 |
| Ryoo, S | 1 |
| Van der Walt, M | 1 |
| Lancaster, J | 1 |
| Odendaal, R | 1 |
| Davis, JG | 1 |
| Shean, K | 1 |
| Farley, J | 1 |
| Ziganshina, LE | 3 |
| Titarenko, AF | 1 |
| Davies, GR | 1 |
| Seddon, JA | 3 |
| Hesseling, AC | 5 |
| Finlayson, H | 1 |
| Fielding, K | 1 |
| Hughes, J | 1 |
| Godfrey-Faussett, P | 1 |
| Schaaf, HS | 5 |
| Zvada, SP | 1 |
| Denti, P | 1 |
| Sirgel, FA | 1 |
| Chigutsa, E | 2 |
| Hatherill, M | 1 |
| Charalambous, S | 1 |
| Mungofa, S | 1 |
| Wiesner, L | 4 |
| Simonsson, US | 1 |
| Jindani, A | 1 |
| Harrison, T | 1 |
| McIlleron, HM | 3 |
| Mpagama, SG | 1 |
| Ndusilo, N | 1 |
| Stroup, S | 1 |
| Kumburu, H | 1 |
| Gratz, J | 1 |
| Houpt, ER | 1 |
| Kibiki, GS | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Kim, DS | 1 |
| Shim, TS | 1 |
| Maimakov, T | 1 |
| Sadykova, L | 1 |
| Kalmataeva, Z | 1 |
| Kurakpaev, K | 1 |
| Šmigelskas, K | 1 |
| Wu, XC | 1 |
| Sun, Q | 1 |
| Li, GL | 1 |
| Liu, ZG | 1 |
| Trollip, AP | 1 |
| Moore, D | 1 |
| Coronel, J | 1 |
| Caviedes, L | 1 |
| Klages, S | 1 |
| Victor, T | 1 |
| Romancenco, E | 1 |
| Crudu, V | 1 |
| Ajbani, K | 1 |
| Vineet, VP | 1 |
| Rodrigues, C | 2 |
| Jackson, RL | 1 |
| Eisenach, K | 1 |
| Garfein, RS | 1 |
| Rodwell, TC | 1 |
| Desmond, E | 1 |
| Groessl, EJ | 1 |
| Ganiats, TG | 1 |
| Catanzaro, A | 1 |
| Apsindzelashvili, R | 1 |
| Thee, S | 3 |
| Garcia-Prats, AJ | 3 |
| Castel, S | 2 |
| Norman, J | 1 |
| Draper, HR | 2 |
| van der Merwe, PL | 1 |
| Syed Sulaiman, SA | 1 |
| Adnan, AS | 1 |
| Haq, Iu | 1 |
| Shah, SS | 1 |
| Ahadi, A | 1 |
| Rautenbach, C | 1 |
| Sun, Z | 1 |
| Xu, Y | 1 |
| Sun, Y | 1 |
| Liu, Y | 1 |
| Zhang, X | 1 |
| Huang, H | 1 |
| Li, C | 2 |
| Zhang, D | 2 |
| Liu, B | 1 |
| Wang, Y | 1 |
| Dalal, A | 1 |
| Pawaskar, A | 1 |
| Das, M | 1 |
| Desai, R | 1 |
| Prabhudesai, P | 1 |
| Chhajed, P | 1 |
| Rajan, S | 1 |
| Reddy, D | 1 |
| Babu, S | 1 |
| Jayalakshmi, TK | 1 |
| Saranchuk, P | 1 |
| Isaakidis, P | 1 |
| Farhat, MR | 1 |
| Franke, MF | 1 |
| Kaur, D | 1 |
| Sloutsky, A | 1 |
| Murray, M | 2 |
| Şimşek, H | 1 |
| Tarhan, G | 1 |
| Cesur, S | 1 |
| Selvakumar, N | 1 |
| Kumar, V | 2 |
| Balaji, S | 1 |
| Prabuseenivasan, S | 1 |
| Radhakrishnan, R | 1 |
| Chandrasekaran, V | 1 |
| Kannan, T | 1 |
| Thomas, A | 2 |
| Arunagiri, S | 1 |
| Dewan, P | 2 |
| Swaminathan, S | 1 |
| Donald, PR | 2 |
| Bakuła, Z | 1 |
| Napiórkowska, A | 1 |
| Kamiński, M | 1 |
| Augustynowicz-Kopeć, E | 1 |
| Zwolska, Z | 1 |
| Bielecki, J | 1 |
| Jagielski, T | 1 |
| Dooley, KE | 1 |
| Khan, MA | 1 |
| Sulaiman, SA | 1 |
| Chien, JY | 3 |
| Chiu, WY | 2 |
| Chien, ST | 2 |
| Chiang, CJ | 1 |
| Yu, CJ | 2 |
| Hsueh, PR | 4 |
| Dong, H | 1 |
| Tan, Y | 1 |
| Deng, Y | 1 |
| Cai, X | 1 |
| Jing, H | 1 |
| Xia, H | 1 |
| Li, Q | 1 |
| Ou, X | 1 |
| Su, B | 1 |
| Li, X | 1 |
| Zhang, Z | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Huan, S | 1 |
| Zhao, Y | 1 |
| Singhal, P | 1 |
| Dixit, P | 2 |
| Singh, P | 1 |
| Jaiswal, I | 1 |
| Singh, M | 1 |
| Jain, A | 4 |
| Forsman, LD | 1 |
| Mansjö, M | 1 |
| Prasad, R | 2 |
| Singh, A | 1 |
| Srivastava, R | 1 |
| Hosmane, GB | 1 |
| Kushwaha, RA | 2 |
| Gomez, JE | 1 |
| Haseley, N | 1 |
| Desjardins, CA | 1 |
| Earl, AM | 1 |
| Hung, DT | 1 |
| Kumar, R | 1 |
| Garg, R | 1 |
| Kant, S | 2 |
| Verma, SK | 1 |
| Kumar, S | 1 |
| Shaheen, Z | 2 |
| Zafar, A | 1 |
| Chaudry, MA | 1 |
| Qayyum, S | 1 |
| Qadeer, E | 1 |
| Agha, N | 1 |
| Rizvi, N | 1 |
| Afridi, MZ | 1 |
| Chima, MK | 1 |
| Khan, AR | 1 |
| Ghafoor, A | 1 |
| Khan, S | 1 |
| Awan, SR | 1 |
| Akhtar, S | 1 |
| Choudry, K | 1 |
| Iqbal, ZH | 1 |
| Ansarie, M | 1 |
| Mokrousov, I | 1 |
| Otten, T | 1 |
| Manicheva, O | 1 |
| Potapova, Y | 1 |
| Vishnevsky, B | 1 |
| Narvskaya, O | 1 |
| Rastogi, N | 1 |
| Cox, HS | 2 |
| Sibilia, K | 1 |
| Feuerriegel, S | 2 |
| Kalon, S | 1 |
| Polonsky, J | 1 |
| Khamraev, AK | 1 |
| Rüsch-Gerdes, S | 2 |
| Mills, C | 1 |
| Niemann, S | 2 |
| Sokolova, GB | 1 |
| Kirtaeva, OV | 1 |
| Lazareva, IaV | 1 |
| Tsybanev, AA | 1 |
| Zarkua, N | 1 |
| Karimovich, HA | 1 |
| Braker, K | 1 |
| Ramachandran, R | 4 |
| Nalini, S | 1 |
| Chandrasekar, V | 1 |
| Dave, PV | 1 |
| Sanghvi, AS | 1 |
| Wares, F | 2 |
| Paramasivan, CN | 2 |
| Narayanan, PR | 2 |
| Sahu, S | 1 |
| Parmar, M | 1 |
| Chadha, S | 1 |
| Chauhan, LS | 1 |
| Chang, KC | 1 |
| Yew, WW | 7 |
| Chan, RC | 1 |
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Louw, GE | 1 |
| Gey van Pittius, NC | 2 |
| Leon, R | 1 |
| Jimenez, A | 1 |
| Hernandez-Pando, R | 1 |
| McEvoy, CR | 1 |
| Grobbelaar, M | 1 |
| van Helden, PD | 2 |
| Victor, TC | 2 |
| Joseph, P | 1 |
| Desai, VB | 1 |
| Mohan, NS | 1 |
| Fredrick, JS | 1 |
| Raman, B | 1 |
| Lee, J | 5 |
| Lee, CH | 1 |
| Kim, DK | 1 |
| Yoon, HI | 1 |
| Kim, JY | 1 |
| Lee, SM | 2 |
| Yang, SC | 1 |
| Lee, JH | 1 |
| Yoo, CG | 2 |
| Lee, CT | 2 |
| Chung, HS | 1 |
| Kim, YW | 2 |
| Han, SK | 2 |
| Yim, JJ | 2 |
| Lai, CC | 1 |
| Tan, CK | 1 |
| Huang, YT | 1 |
| Liao, CH | 1 |
| Jeon, CY | 1 |
| Kang, H | 1 |
| Kim, M | 1 |
| Murray, MB | 1 |
| Cho, EH | 1 |
| Chen, X | 1 |
| Kong, F | 1 |
| Wang, Q | 1 |
| Gilbert, GL | 1 |
| Said, HM | 2 |
| Kock, MM | 2 |
| Ismail, NA | 2 |
| Baba, K | 2 |
| Omar, SV | 2 |
| Osman, AG | 2 |
| Hoosen, AA | 2 |
| Ehlers, MM | 2 |
| Ramos, E | 1 |
| Fissette, K | 1 |
| de Rijk, P | 1 |
| Palomino, JC | 2 |
| Martin, A | 2 |
| Pitaksajjakul, P | 1 |
| Worakhunpiset, S | 1 |
| Chaiprasert, A | 1 |
| Boonyasopun, J | 1 |
| Ramasoota, P | 1 |
| Bergval, I | 1 |
| Böttger, EC | 1 |
| Bosman, M | 1 |
| Coetzee, G | 1 |
| Anthony, RM | 1 |
| Diacon, AH | 1 |
| Pym, A | 1 |
| Grobusch, M | 1 |
| Patientia, RF | 1 |
| Mahanyele, R | 1 |
| Bantubani, N | 1 |
| Narasimooloo, R | 1 |
| De Marez, T | 1 |
| van Heeswijk, R | 1 |
| Lounis, N | 1 |
| Meyvisch, P | 1 |
| Andries, K | 1 |
| McNeeley, DF | 1 |
| Meredith, S | 1 |
| Padayatchi, N | 1 |
| Harding, J | 1 |
| Moodley, P | 1 |
| Mac Kenzie, WR | 1 |
| Weiner, M | 1 |
| McIlleron, H | 1 |
| Kirkpatrick, CM | 1 |
| Yano, S | 1 |
| Kobayashi, K | 1 |
| Ikeda, T | 2 |
| Saheer, S | 1 |
| Hassan, G | 1 |
| Parengal, J | 1 |
| Mphahlele, M | 1 |
| Lakshmi, R | 1 |
| Rahman, F | 1 |
| Chauny, JV | 1 |
| Lorrot, M | 1 |
| Prot-Labarthe, S | 1 |
| De Lauzanne, A | 1 |
| Doit, C | 1 |
| Géréral, T | 1 |
| Bourdon, O | 1 |
| Pasipanodya, J | 1 |
| Srivastava, S | 1 |
| Gumbo, T | 1 |
| Papastavros, T | 1 |
| Dolovich, LR | 1 |
| Holbrook, A | 1 |
| Whitehead, L | 1 |
| Loeb, M | 1 |
| Richeldi, L | 1 |
| Covi, M | 1 |
| Ferrara, G | 1 |
| Franco, F | 1 |
| Vailati, P | 1 |
| Meschiari, E | 1 |
| Fabbri, LM | 1 |
| Velluti, G | 1 |
| Chulavatnatol, S | 2 |
| Chindavijak, B | 2 |
| Chierakul, N | 2 |
| Klomsawat, D | 2 |
| Chen, QL | 1 |
| Chen, L | 1 |
| Yin, JJ | 1 |
| Chan, CK | 2 |
| Leung, CC | 2 |
| Chau, CH | 6 |
| Tam, CM | 2 |
| Wong, PC | 3 |
| Walwaikar, PP | 1 |
| Morye, VK | 1 |
| Gawde, AS | 1 |
| Park, SK | 1 |
| Lee, WC | 1 |
| Lee, DH | 1 |
| Han, L | 1 |
| Seung, KJ | 1 |
| Zheng, XM | 1 |
| Li, SM | 1 |
| Xing, BC | 1 |
| Kam, KM | 1 |
| Yip, CW | 1 |
| Ramarokoto, H | 1 |
| Andrianasolo, D | 1 |
| Rasolonavalona, T | 1 |
| Ramaroson, F | 1 |
| Razafitsiarovana, I | 1 |
| Vincent, V | 1 |
| Ratsimba, L | 1 |
| Rasolofo Razanamparany, V | 1 |
| Ward, HA | 1 |
| Marciniuk, DD | 1 |
| Hoeppner, VH | 1 |
| Jones, W | 1 |
| Portaels, F | 3 |
| Rafailidis, PI | 1 |
| Avramopoulos, I | 1 |
| Sapkas, G | 1 |
| Falagas, ME | 1 |
| Vizel, AA | 1 |
| Squire, SB | 2 |
| Mirsaeidi, SM | 1 |
| Tabarsi, P | 1 |
| Khoshnood, K | 1 |
| Pooramiri, MV | 1 |
| Rowhani-Rahbar, A | 1 |
| Mansoori, SD | 1 |
| Masjedi, H | 1 |
| Zahirifard, S | 1 |
| Mohammadi, F | 1 |
| Farnia, P | 1 |
| Masjedi, MR | 1 |
| Velayati, AA | 1 |
| Kim, HJ | 1 |
| Kang, CH | 1 |
| Kim, YT | 1 |
| Sung, SW | 1 |
| Kim, JH | 1 |
| Shim, YS | 1 |
| Tada, A | 1 |
| Kawata, N | 1 |
| Shibayama, T | 1 |
| Takahashi, S | 1 |
| Hirano, A | 1 |
| Kimura, G | 1 |
| Takeuchi, M | 1 |
| Okada, C | 1 |
| Soda, R | 1 |
| Takahashi, K | 1 |
| Sulochana, S | 1 |
| Narayanan, S | 1 |
| Suganthi, C | 1 |
| Umubyeyi, A | 1 |
| Rigouts, L | 1 |
| Shamputa, IC | 1 |
| Dediste, A | 1 |
| Struelens, M | 1 |
| von Gottberg, A | 1 |
| Klugman, KP | 1 |
| Cohen, C | 1 |
| Wolter, N | 1 |
| de Gouveia, L | 1 |
| du Plessis, M | 1 |
| Mpembe, R | 1 |
| Quan, V | 1 |
| Whitelaw, A | 1 |
| Hoffmann, R | 1 |
| Govender, N | 1 |
| Meiring, S | 1 |
| Smith, AM | 1 |
| Schrag, S | 1 |
| Reichman, LB | 1 |
| Elliott, AM | 1 |
| Berning, SE | 5 |
| Iseman, MD | 4 |
| Mühlberger, F | 1 |
| Nturanye, F | 1 |
| Nasbimana, J | 1 |
| Madsen, L | 1 |
| Horn, DL | 1 |
| Hewlett, D | 1 |
| Alfalla, C | 1 |
| Peterson, S | 1 |
| Opal, SM | 1 |
| Wong, CF | 1 |
| Ruggiero, SL | 1 |
| Hilton, E | 1 |
| Braun, TW | 1 |
| Maranetra, KN | 2 |
| Zhang, LX | 1 |
| Suo, J | 1 |
| Yu, MC | 1 |
| Lee, CN | 1 |
| Chiang, CY | 1 |
| Lin, TP | 1 |
| Hadiarto, M | 1 |
| Tjandra, YA | 1 |
| Hudoyo, A | 2 |
| Iwanaga, T | 1 |
| Yokota, K | 1 |
| Kishikawa, R | 1 |
| Tsurutani, H | 1 |
| Hirose, T | 1 |
| Nishima, S | 1 |
| Au, KF | 1 |
| Michałowska-Mitczuk, D | 1 |
| Kuś, J | 1 |
| Huitt, GA | 1 |
| Arora, VK | 1 |
| Tumbanatham, A | 2 |
| Ye, Z | 1 |
| Pei, X | 1 |
| Telzak, EE | 1 |
| Chirgwin, KD | 1 |
| Nelson, ET | 1 |
| Matts, JP | 1 |
| Sepkowitz, KA | 1 |
| Benson, CA | 1 |
| Perlman, DC | 1 |
| El-Sadr, WM | 1 |
| Zhang, Y | 1 |
| Qian, H | 1 |
| Chen, M | 1 |
| Mangunnegoro, H | 1 |
| Casal, M | 1 |
| Ruiz, P | 1 |
| Herreras, A | 1 |
| Cherry, TA | 1 |
| Vinodkumar, S | 1 |
| Grimaldo, ER | 1 |
| Tupasi, TE | 1 |
| Rivera, AB | 1 |
| Quelapio, MI | 1 |
| Cardaño, RC | 1 |
| Derilo, JO | 1 |
| Belen, VA | 1 |
| Tahaoğlu, K | 1 |
| Törün, T | 1 |
| Sevim, T | 1 |
| Ataç, G | 1 |
| Kir, A | 1 |
| Karasulu, L | 1 |
| Ozmen, I | 1 |
| Kapakli, N | 1 |
| Reid, J | 1 |
| Marciniuk, D | 1 |
| Hoeppner, V | 1 |
| Pracharktam, R | 1 |
| Angkananukool, K | 1 |
| Vibhagool, A | 1 |
| Padeĭskaia, EN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial[NCT04298905] | 200 participants (Anticipated) | Interventional | 2022-03-10 | Recruiting | |||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in[NCT00000796] | 525 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
7 reviews available for ofloxacin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofl | 2013 |
Fluoroquinolones for the treatment of tuberculosis in children.
Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; F | 2015 |
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistanc | 2010 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2008 |
Treatment of multidrug-resistant tuberculosis in Thailand.
Topics: Acquired Immunodeficiency Syndrome; Ambulatory Care Facilities; Clinical Trials as Topic; Drug Resis | 1996 |
Treatment of multidrug-resistant tuberculosis in China.
Topics: Antitubercular Agents; China; Clinical Trials as Topic; Drug Therapy; Financing, Organized; Health P | 1996 |
13 trials available for ofloxacin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; M | 2014 |
[Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
Topics: Adult; Antitubercular Agents; Arthralgia; Diarrhea; Drug Resistance, Multiple, Bacterial; Drug Thera | 2008 |
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
Topics: Adult; Antibiotics, Antitubercular; Communicable Disease Control; Cycloserine; Directly Observed The | 2011 |
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; | 2012 |
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxa | 2012 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical | 2004 |
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; Cycloserine; Drug Therapy, Combination; Fe | 2005 |
Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.
Topics: Health Personnel; Humans; Occupational Diseases; Ofloxacin; Premedication; Pyrazinamide; Tuberculosi | 1994 |
Treatment of multidrug-resistant tuberculosis in Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Drug Resistance, Multiple; Drug Therapy, C | 1996 |
Treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adult; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Indonesia; Isoniazid; M | 1996 |
[Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients].
Topics: Adult; Aminosalicylic Acid; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Multiple; | 1997 |
[Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoscopy; Catheterization, Periph | 1997 |
Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adolescent; Adult; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Treatment Ou | 1999 |
125 other studies available for ofloxacin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
Topics: Alkaloids; Antitubercular Agents; Benzylisoquinolines; Drug Resistance, Multiple, Bacterial; Humans; | 2012 |
Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; DNA, Bacterial; Ethambutol; Exten | 2021 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambuto | 2022 |
Molecular Detection of Ofloxacin and Kanamycin Resistance in Patients with MDR and Non-MDR TB from Suburban Districts in Hangzhou, China, 2019-2020.
Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuber | 2022 |
Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
Topics: Amikacin; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; | 2022 |
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Ethionamide; Female; HIV Infections; Ho | 2023 |
Comparison of the Diagnostic Performance of MeltPro and Next-Generation Sequencing in Determining Fluoroquinolone Resistance in Multidrug-Resistant Tuberculosis Isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; High-Throughput Nuc | 2023 |
ODELAM, rapid sequence-independent detection of drug resistance in isolates of
Topics: Antibiotics, Antitubercular; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Humans; | 2020 |
Genotype analysis of ofloxacin-resistant multidrug-resistant
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Genotype; Hu | 2020 |
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Topics: Antitubercular Agents; Codon; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fema | 2020 |
Sequence-based detection of first-line and second-line drugs resistance-associated mutations in Mycobacterium tuberculosis isolates in Isfahan, Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Capreomycin; DNA Mutational Analysi | 2020 |
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; M | 2021 |
Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.
Topics: Acetyltransferases; Adult; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Catalase; Chi | 2021 |
Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; DNA Gyrase; Drug Resistan | 2018 |
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbi | 2017 |
Impact of
Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Base Sequence; Capreomycin; DNA Gyras | 2017 |
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; My | 2017 |
Frequency and implications of ofloxacin resistance among previously treated tuberculosis patients.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Humans; Male; Mycobacterium tuberc | 2017 |
Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Topics: Adult; Antitubercular Agents; China; Cohort Studies; Extensively Drug-Resistant Tuberculosis; Female | 2017 |
PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Topics: Antitubercular Agents; Base Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambut | 2017 |
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinol | 2018 |
Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Creatinine; Drug Resistance, Multiple, Bac | 2017 |
Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China.
Topics: Antitubercular Agents; Bacteriological Techniques; China; DNA Gyrase; DNA Mutational Analysis; Drug | 2017 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sen | 2018 |
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Topics: Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Mutational Analysis; Drug Resistanc | 2018 |
Three new platinum complexes containing fluoroquinolones and DMSO: Cytotoxicity and evaluation against drug-resistant tuberculosis.
Topics: Cell Line, Tumor; Cell Survival; Ciprofloxacin; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor | 2018 |
Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cohort Studies; Drug Resistance, Bacterial; Female; | 2018 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; | 2018 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Rela | 2019 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-R | 2013 |
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Topics: Acetyltransferases; Amidohydrolases; Amikacin; Antigens, Bacterial; Bacterial Proteins; Capreomycin; | 2013 |
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female | 2013 |
Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.
Topics: Antitubercular Agents; Child, Preschool; Ethambutol; Female; HIV Infections; Humans; Infant; Infant, | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon | 2014 |
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroqui | 2014 |
Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Capreomycin; Cycloserine; Drug Costs; Female; H | 2013 |
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China.
Topics: Antitubercular Agents; Bacterial Proteins; Capreomycin; Genotype; Humans; Isoniazid; Kanamycin; Micr | 2014 |
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones | 2014 |
Performance of the MTBDRsl assay in Georgia.
Topics: Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant | 2014 |
Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Levofloxacin; Ma | 2014 |
Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycoba | 2014 |
Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?
Topics: Age Factors; Antitubercular Agents; Bacterial Proteins; Child; Child, Preschool; Drug Resistance, Mu | 2014 |
Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.
Topics: Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Genotype; Micr | 2014 |
Rapid molecular screening for multidrug-resistant tuberculosis in a resource-limited region of China.
Topics: Antitubercular Agents; Bacterial Proteins; China; DNA, Bacterial; Drug Resistance, Multiple, Bacteri | 2014 |
Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, | 2015 |
Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tes | 2015 |
[Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
Topics: Acetamides; Antitubercular Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Ethionamide; | 2015 |
High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; India; M | 2015 |
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Topics: Adult; Aged; Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Gyrase; Drug Resistanc | 2016 |
Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 2015 |
Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Drug Administration Schedule; Drug Resista | 2015 |
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Topics: Anti-Bacterial Agents; Asian People; Codon; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Europe | 2016 |
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China.
Topics: Amikacin; China; Extensively Drug-Resistant Tuberculosis; Humans; Kanamycin; Microbial Sensitivity T | 2016 |
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
Topics: Aged; Antitubercular Agents; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolo | 2016 |
A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
Topics: Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Ind | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; | 2016 |
Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Cohort Studies; Cycloserine; Drug Therapy, Combination; Ethambutol; Et | 2016 |
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
Topics: Antitubercular Agents; Clone Cells; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Evolution, Mol | 2016 |
High correlation of clinical criteria in the diagnosis of drug-resistant TB and prevalence of ofloxacin resistance.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuber | 2016 |
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Drug Administration Schedule; Ethambutol | 2017 |
Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
Topics: Adolescent; Adult; Antitubercular Agents; Cross-Sectional Studies; Extensively Drug-Resistant Tuberc | 2017 |
Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia.
Topics: Antitubercular Agents; Bacterial Proteins; DNA Gyrase; Genotype; Mycobacterium tuberculosis; Ofloxac | 2008 |
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
Topics: Analysis of Variance; Antitubercular Agents; Cross Infection; Extensively Drug-Resistant Tuberculosi | 2008 |
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; Extensively Drug-Resis | 2009 |
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
Topics: Antitubercular Agents; Bacteriological Techniques; Colony Count, Microbial; Drug Resistance, Multipl | 2009 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacterial | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Res | 2011 |
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Bacteri | 2011 |
Clustering of Mycobacterium tuberculosis strains from foreign-born patients in Korea.
Topics: Antitubercular Agents; Cluster Analysis; DNA Transposable Elements; Emigrants and Immigrants; Female | 2011 |
Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Isoniaz | 2011 |
Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs.
Topics: Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; Drug Re | 2012 |
Integrated detection of multi- and extensively drug-resistant tuberculosis using the nitrate reductase assay.
Topics: Antitubercular Agents; Colorimetry; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; E | 2012 |
gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand.
Topics: Antibiotics, Antitubercular; DNA Gyrase; Drug Resistance, Bacterial; Humans; Mutation; Mycobacterium | 2011 |
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.
Topics: Amikacin; Antitubercular Agents; Bacterial Typing Techniques; Base Sequence; DNA Gyrase; Drug Resist | 2012 |
Multidrug-resistant tuberculosis that required 2 years for diagnosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Diagnosis, Differential; Humans; Male; Ofloxacin; | 2012 |
Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
Topics: Adult; Antitubercular Agents; Clarithromycin; Clofazimine; Cycloserine; Diagnosis, Differential; Dru | 2012 |
Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Capreomycin; Child; Cluster Analysis; Drug Resistanc | 2012 |
Consistency of standard laboratory strain Mycobacterium tuberculosis H 37 Rv with ethionamide susceptibility testing.
Topics: Drug Resistance, Microbial; Ethionamide; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacteri | 2012 |
Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; India; Kanamycin; Kanamycin Resis | 2012 |
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; | 2012 |
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Female; Humans; Male; Ofloxacin; Tuberculosis, Multidrug-Resistant | 2012 |
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Levofloxacin; Male; | 2002 |
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; | 2002 |
Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Area Under Curve; Chromatography, High Pressure | 2003 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le | 2003 |
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.
Topics: Anti-Infective Agents; Female; Hong Kong; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Retros | 2003 |
Ofloxacin in multidrug resistant tuberculosis.
Topics: Anti-Infective Agents; Comorbidity; HIV Infections; Humans; Ofloxacin; Tuberculosis, Multidrug-Resis | 2003 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Communicable Disease Control; Cycloserine; D | 2004 |
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial; | 2003 |
Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants.
Topics: Capreomycin; Cycloserine; Drug Therapy, Combination; Emigration and Immigration; Ethambutol; Ethiona | 2005 |
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.
Topics: Anti-Bacterial Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; | 2005 |
Multidrug-resistant tuberculous spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Biopsy, Fine-Needle; Bone Transplantation; Cycloserine; Discitis; Drug Therap | 2006 |
Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Drug Resistance, Multiple, Bacterial; Female; Humans; Lung | 2006 |
[In vitro antituberculous activity of ofloxacin and levofloxacin against multidrug-resistant tuberculosis and clinical outcomes].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Female; | 2006 |
Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity | 2007 |
Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Topics: Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Clarithromycin; Drug Resi | 2008 |
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Child, Preschool; Cross Infection; | 2008 |
Tuberculosis drug resistance comes full circle.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Ofloxacin; Pneumoc | 2008 |
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.
Topics: Aged; Antitubercular Agents; Chronic Disease; Empyema, Tuberculous; Ethambutol; Humans; Male; Ofloxa | 1995 |
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Cycloserine; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1995 |
Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin.
Topics: Adult; Cycloserine; Depression; Drug Therapy, Combination; Humans; Male; Middle Aged; Ofloxacin; Sei | 1993 |
Trismus and preauricular swelling in a 20-year-old black woman.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Capreomycin; Diagnosis, Differential; Edema; Etha | 1996 |
[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Clavulanic | 1997 |
Advice on treatment of drug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Ciprofloxacin; Cycloserine; Drug Monitoring; Drug Resistance, Microbia | 1997 |
Levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Hu | 1997 |
[Treatment of patients for chronic pulmonary tuberculosis with expectoration--selection and tolerance to drugs].
Topics: Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Humans; Incidence | 1997 |
Levofloxacin for drug-resistant Mycobacterium tuberculosis.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Humans; Levofloxacin; Mycobacterium tube | 1998 |
Severe arthropathy with ofloxacin in two cases of MDR tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Joint Diseases; Ofloxacin; Tube | 1998 |
Fluoroquinolones and tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tubercul | 1998 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Quinolones and multidrug-resistant tuberculosis.
Topics: Anti-Infective Agents; Humans; Ofloxacin; Prevalence; Thailand; Tuberculosis, Multidrug-Resistant; T | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxac | 2000 |
Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Female; HIV Seropos | 2000 |
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; In | 2001 |
Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis.
Topics: Adult; Antitubercular Agents; Arthritis; Drug Interactions; Drug Therapy, Combination; Female; Human | 2000 |
Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Chromatography, H | 2001 |
Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
Topics: Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Drug Resistance, Mu | 2001 |
The treatment of multidrug-resistant tuberculosis in Turkey.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid | 2001 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levoflo | 2002 |
In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
Topics: Coloring Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbia | 2001 |
[Combination chemotherapy of drug-resistant tuberculosis with inclusion of ofloxacin (zanocin)].
Topics: Anti-Infective Agents; Antitubercular Agents; Humans; In Vitro Techniques; Microbial Sensitivity Tes | 2001 |
Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB)--a balanced view?
Topics: Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Humans; Male; Microbial Sensiti | 2002 |